Decision: Favourable
Study Title:
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)
NREC Code:
23-NREC-CT-009
Decision:
Favourable
Meeting Date:
08/02/2023
Study Type:
CT application
Principal Investigator:
Prof Orla Hardiman
PI Institution:
Beaumont Hospital
Sponsor:
Amylyx Pharmaceuticals Inc